The effect of transmitted HIV-1 drug resistance on pre-therapy viral load

AIDS

Volumn 24, Issue 12, 2010, Pages 1917-1922

  Harrison, Linda ^a   Castro, Hannah ^a   Cane, Patricia ^b   Pillay, Deenan ^b,c   Booth, Clare ^c   Phillips, Andrew ^c   Geretti, Anna Maria ^c,d   Dunn, David ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

HIV; M184V I; Pre therapy; Transmitted drug resistance; Viral load

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CD4 LYMPHOCYTE COUNT; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; GENOTYPE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; RNA, VIRAL; VIRAL LOAD;

EID: 77954757141     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833c1d93     Document Type: Article

References (31)

1. Dykes C, Demeter LM. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev 2007; 20:550-578.
2. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001; 14:23-28.
3. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76:1753-1761.
4. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, de Wolf F, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 2004; 18:1571-1577.
5. Cong ME, Heneine W, Garcia-Lerma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007; 81:3037-3041.
6. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200:1503-1508.
7. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007; 59:517-524.
8. Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, et al. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination anti-retroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 2008; 48:324-333.
9. de Mendoza C, Ortiz M, Pérez-Hoyos S, Corral A, Garćia-Sáinz A, del Amo J, et al. Impact of transmission of drug-resistant HIV viruses on viral load, CD4 counts and CD4 decline in recent seroconverters. Antiviral Ther 2003; 8:S88.
10. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331:1368.
11. The UK Collaborative HIV Cohort (UK CHIC) Study Group. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-124.
12. Sabin CA, Hill T, LampeF, Matthias R, Bhagani S, Gilson R, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005; 330:695.
13. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-223. (Pubitemid 46036930)
14. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-3800.
15. Taffe P, May M. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. Stat Med 2008; 27:4835-4853.
16. Dorrucci M, Rezza G, Porter K, Phillips A. Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis 2007; 195:525-534.
17. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179:68-73.
18. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-852.
19. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197:707-713.
20. Montes B, Vergne L, Peeters M, Reynes J, Delaporte E, Segondy M. Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr 2004; 35:329-336.
21. The CASCADE Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003; 34:76-83.
22. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20:795-803.
23. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4R cells per cubic millimeter. North American HIV Working Party.N Engl J Med 1995; 333:1662-1669.
24. Phillips A, Pezzotti P. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58.
25. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
26. Cane PA. Stability of transmitted drug-resistant HIV-1 species. Curr Opin Infect Dis 2005; 18:537-542.
27. Turner D, Brenner B, Routy JP, Moisi D, Rosberger Z, Roger M, Wainberg MA. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37:1627-1631. (Pubitemid 39658205)
28. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82:5510-5518.
29. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, Wainberg 'Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004; 18:1653-1660.
30. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13:F123-F127.
31. Little SJ, Grant RM, Daar ES, Markowitz M, Hecht FM, Johnson V, et al. Transmitted NNRTI drug resistance is associated with higher steady-state viral load measures in untreated subjects with primary HIV infection. Antiviral Ther 2004; 9:S58.